We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sanofi-Aventis Addresses Ketek Findings as Competitor Moves In
Sanofi-Aventis Addresses Ketek Findings as Competitor Moves In
December 29, 2006
A joint FDA advisory committee recommendation of narrower indications for, and increased warnings on, sanofi-aventis’ antibiotic Ketek has the company taking steps to respond as a competitor may begin grabbing market share.